Literature DB >> 22443086

Tris[2-(acryloyloxy)ethyl]isocyanurate cross-linked low-molecular-weight polyethylenimine as gene delivery carriers in cell culture and dystrophic mdx mice.

Mingxing Wang1, Jay D Tucker, Peijuan Lu, Bo Wu, Caryn Cloer, Qilong Lu.   

Abstract

Hyperbranched poly(ester amine)s (PEAs) were successfully synthesized by Michael addition reaction between tris[2-(acryloyloxy)ethyl]isocyanurate (TAEI) and low-molecular-weight polyethylenimine (LPEI, M(w) 0.8k, 1.2k, and 2.0k) and evaluated in vitro and in vivo as gene carriers. PEAs effectively condensed plasmid DNA with particle sizes below 200 nm and surface charges between 11.5 and 33.5 mV under tested doses [at the ratios 2-10:1 of polymer/pDNA(w/w)]. The PEAs showed significantly lower cytotoxicities when compared with PEI 25k in two different cell lines. The PEAs (C series) composed of PEI 2k showed higher transgene expression compared to PEAs of PEI 0.8k (A series) or 1.2k (B series). Highest gene transfection efficiency in CHO, C2C12 myoblast, and human skeletal muscle (HSK) cell lines was obtained with TAEI/PEI-2K (C12) at a ratio of 1:2. Both C12, C14(TAEI/PEI-2K at a ratio of 1:4) demonstrated 5-8-fold higher gene expression as compared with PEI 25k in mdx mice in vivo through intramuscular administration. No obvious muscle damage was observed with these new polymers. Higher transfection efficiency and lower toxicity indicate the potential of the biodegradable PEAs as safe and efficient transgene delivery vectors.
© 2012 American Chemical Society

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22443086     DOI: 10.1021/bc200674e

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  6 in total

1.  Evaluation of Tris[2-(acryloyloxy)ethyl]isocyanurate cross-linked polyethylenimine as antisense morpholino oligomer delivery vehicle in cell culture and dystrophic mdx mice.

Authors:  Mingxing Wang; Bo Wu; Jay D Tucker; Peijuan Lu; Caryn Cloer; Qi Long Lu
Journal:  Hum Gene Ther       Date:  2014-04-25       Impact factor: 5.695

Review 2.  Nanotherapy for Duchenne muscular dystrophy.

Authors:  Michael E Nance; Chady H Hakim; N Nora Yang; Dongsheng Duan
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2017-04-11

Review 3.  Nanomedicine, a valuable tool for skeletal muscle disorders: Challenges, promises, and limitations.

Authors:  Valentina Colapicchioni; Francesco Millozzi; Ornella Parolini; Daniela Palacios
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2022-01-29

4.  A linear polyethylenimine mediated siRNA-based therapy targeting human epidermal growth factor receptor in SPC-A1 xenograft mice.

Authors:  Pinghai Zhang; Nuo Xu; Lei Zhou; Xin Xu; Yuehong Wang; Ka Li; Zhaochong Zeng; Xiangdong Wang; Xin Zhang; Chunxue Bai
Journal:  Transl Respir Med       Date:  2013-02-22

Review 5.  Nanomedicine for Treating Muscle Dystrophies: Opportunities, Challenges, and Future Perspectives.

Authors:  Zaheer Ahmed; Rizwan Qaisar
Journal:  Int J Mol Sci       Date:  2022-10-10       Impact factor: 6.208

Review 6.  Recent advances of biomaterials in biotherapy.

Authors:  Ling Li; Zhi-Yao He; Xia-Wei Wei; Yu-Quan Wei
Journal:  Regen Biomater       Date:  2016-03-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.